LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds

Anticancer Res. 2010 Apr;30(4):1183-8.

Abstract

Background: LA-12 is a new platinum (IV) drug with promising cytotoxic effects in a wide range of cancer cell lines. Its confluence-dependent effects were compared with cisplatin (CDDP) and oxaliplatin (L-OHP) in HT-29 cells.

Materials and methods: Cytotoxicity was determined by MTT test, eosin exclusion assay, and cell number quantification. The cell cycle was analysed using propidium iodide DNA staining (flow cytometry), apoptosis by phosphatidylserine externalisation (annexin-V assay), mitochondrial membrane potential by flow cytometry, nuclear morphology by means of fluorescence microscopy, and PARP cleavage by Western blotting.

Results: While L-OHP and CDDP were practically inactive in the subconfluent cell population, LA-12 showed a similar toxicity in both subconfluent and growing populations. All compounds induced apoptosis, although with different potentials.

Conclusion: LA-12 was able to overcome confluence-dependent resistance of HT-29 cells observed for other platinum compounds, which may have potential therapeutic use in slowly growing tumours.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Amantadine / analogs & derivatives*
  • Amantadine / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Adhesion / drug effects
  • Cisplatin / pharmacology
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • HT29 Cells
  • Humans
  • Organoplatinum Compounds / pharmacology*
  • Oxaliplatin

Substances

  • Antineoplastic Agents
  • Organoplatinum Compounds
  • bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)
  • Oxaliplatin
  • Amantadine
  • Cisplatin